Inebilizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CD19 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6504H10080N1732O2044S44 |
Molar mass | 147 kDa |
Inebilizumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer, systemic sclerosis and multiple sclerosis.[1][2]
This drug was developed by MedImmune, LLC.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Inebilizumab, American Medical Association.
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.